Antimicrobial Susceptibility, AFB/Mycobacterium tuberculosis Primary Panel
Also known as: MA MTBPRIM
Use
This test screens isolates of Mycobacterium tuberculosis complex for drug resistance to first-line antimycobacterial agents including rifampin, isoniazid, and ethambutol. It is essential in guiding the treatment of tuberculosis by determining the susceptibility of Mycobacterium tuberculosis isolates, aiding in the management of infections caused by this pathogen, and preventing the spread of resistant strains.
Special Instructions
Transport the specimen in a sealed container with pure culture on solid or liquid media, placed in an individually sealed bag, following Infectious Substance, Category A shipping guidelines. Testing for pyrazinamide resistance mutations should be referred to a local public health laboratory or the CDC.
Limitations
The procedure does not provide quantitative MIC values but uses single critical concentrations for each antimycobacterial agent defined by the United States Public Health Service. Only the drugs ethambutol, isoniazid, and rifampin are tested, and the methodology does not account for serial dilutions or susceptibility of Mycobacterium tuberculosis resistant to secondary agents unless resistant to rifampin or any two primary agents.
Methodology
Culture-based
Biomarkers
LOINC Codes
- 29576-6
Result Turnaround Time
21-28 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Not provided
Minimum Volume
Not provided
Container
Sealed container with pure culture on solid or liquid media
Collection Instructions
Actively growing isolate of Mycobacterium tuberculosis in pure culture. Transport in a sealed container placed in an individually sealed bag, according to Infectious Substance, Category A guidelines.
Causes for Rejection
Mixed cultures or non-viable organisms. Organisms submitted on agar plate.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 weeks |
| Refrigerated | 2 weeks |
| Frozen | Unacceptable |
